Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC13A5 | Q86YT5 | 1/20 | 0.46 |
| ▸ | HTR2A | P28223 | 2/20 | 0.43 |
| ▸ | HTR2C | P28335 | 2/20 | 0.43 |
| ▸ | KDM1A | O60341 | 5/20 | 0.43 |
| ▸ | MAOA | P21397 | 2/20 | 0.43 |
| ▸ | MAOB | P27338 | 1/20 | 0.43 |
| ▸ | APLNR | P35414 | 1/20 | 0.40 |
| ▸ | BTK | Q06187 | 1/20 | 0.40 |
| ▸ | NFE2L2 | Q16236 | 2/20 | 0.38 |
| ▸ | HTR2B | P41595 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | IDH1 | O75874 | 1/20 | 0.36 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.35 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29138539 | 0.84 | SLC13A5 (0.51) | SLC13A5HTR2AHTR2CKDM1AMAOA | |
| SCHEMBL91503 | 0.81 | SLC13A5 (0.50) | SLC13A5HTR2AHTR2CKDM1AMAOA | |
| SCHEMBL6588356 | 0.79 | SLC13A5 (0.49) | SLC13A5HTR2AHTR2CKDM1AMAOA | |
| SCHEMBL2753934 | 0.76 | SLC13A5 (0.41) | SLC13A5HTR2AHTR2CKDM1AMAOA | |
| SCHEMBL18440 | 0.76 | MEN1 (0.60) | SLC13A5HTR2AHTR2CKDM1AMAOA | |
| SCHEMBL18291875 | 0.76 | SLC13A5 (0.49) | SLC13A5HTR2AHTR2CKDM1AMAOA | |
| SCHEMBL1645573 | 0.76 | P2RX7 (0.41) | MEN1KMT2A | |
| SCHEMBL2960548 | 0.76 | SLC13A5 (0.49) | SLC13A5HTR2AHTR2CKDM1AMAOA | |
| SCHEMBL31365171 | 0.76 | MEN1 (0.60) | SLC13A5HTR2AHTR2CKDM1AMAOA | |
| SCHEMBL129593 | 0.76 | KDM1A (0.46) | SLC13A5HTR2AHTR2CKDM1AMAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2970305-A1 | MODULATORS OF METHYL MODIFYING ENZYMES, COMPOSITIONS AND USES THEREOF | Constellation Pharmaceuticals, Inc. (US) | 2016-01-20 | — | — | EP | disclosed |
| WO-2015187934-A1 | FUNCTIONALIZED HETROARYL ENONES EXHIBITING NRF2 ACTIVATION AND THEIR METHOD OF USE | CUREVEDA, LLC (US) | 2015-12-10 | — | — | WO | disclosed |
| WO-2014151142-A1 | MODULATORS OF METHYL MODIFYING ENZYMES, COMPOSITIONS AND USES THEREOF | CONSTELLATION PHARMACEUTICALS, INC. (US) | 2014-09-25 | — | — | WO | disclosed |
| EP-1254904-B1 | NOVEL PIPERIDINE COMPOUNDS AND DRUGS CONTAINING THE SAME | EISAI CO LTD (JP) | 2006-05-24 | — | — | EP | disclosed |
| US-6784192-B2 | NA+ CHANNEL INHIBITORY ACTION IS USEFUL FOR THERAPY AND PREVENTION FOR EXAMPLE, ARRHYTHMIA, VARIOUS NEURALGIAS AND ANALGESIC | EISAI CO., LTD. (JP) | 2004-08-31 | — | — | US | disclosed |
| US-20030220368-A1 | Novel piperidine compouds and drugs containing the same | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2003-11-27 | — | — | US | disclosed |
| EP-1254904-A1 | NOVEL PIPERIDINE COMPOUNDS AND DRUGS CONTAINING THE SAME | Eisai Co., Ltd. (JP) | 2002-11-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030220368-A1 | Novel piperidine compouds and drugs containing the same | TRPV1, CACNA1D, KCND2 | SLC13A5 202/4885HTR2A 439/4885HTR2C 353/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.